Prefrontal cortex and spinal cord mediated anti-neuropathy and analgesia induced by sarcosine, a glycine-T1 transporter inhibitor

Pain

Volumn 145, Issue 1-2, 2009, Pages 176-183

  Centeno, Maria V ^a   Mutso, Amelia ^a   Millecamps, Magali ^b   Vania Apkarian, A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Allodynia; d Cycloserine; Gavage; Nerve injury; Tactile sensitivity

Indexed keywords

GLYCINE TRANSPORTER 1; SARCOSINE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; MALE; NERVE INJURY; NEUROPATHIC PAIN; NEUROPATHY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SPARED NERVE INJURY; SPINAL CORD;

ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; COLD TEMPERATURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; EXPLORATORY BEHAVIOR; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; PAIN MEASUREMENT; PAIN THRESHOLD; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SARCOSINE; SCIATICA; SPINAL CORD; TIME FACTORS;

EID: 69049113834     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2009.06.014     Document Type: Article

References (35)

1. Apkarian A.V., Bushnell M.C., Treede R.D., and Zubieta J.K. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 9 (2005) 463-484
2. Apkarian A.V., Sosa Y., Sonty S., Levy R.E., Harden R., Parrish T., and Gitelman D. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci 24 (2004) 10410-10415
3. Baliki M.N., Chialvo D.R., Geha P.Y., Levy R.M., Harden R.N., Parrish T.B., and Apkarian A.V. Chronic pain and the emotional brain: specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. J Neurosci 26 (2006) 12165-12173
4. Bergeron F., Otto A., Blache P., Day R., Denoroy L., Brandsch R., and Bataille D. Molecular cloning and tissue distribution of rat sarcosine dehydrogenase. Eur J Biochem 257 (1998) 556-561
5. Bergeron R., Meyer T.M., Coyle J.T., and Greene R.W. Modulation of N-methyl-d-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 95 (1998) 15730-15734
6. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53 (1994) 55-63
7. Chen L., Muhlhauser M., and Yang C.R. Glycine transporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 89 (2003) 691-703
8. Choi Y., Yoon Y.W., Na H.S., Kim S.H., and Chung J.M. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 59 (1994) 369-376
9. Decosterd I., and Woolf C.J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87 (2000) 149-158
10. Eschenbrenner M., and Jorns M.S. Cloning and mapping of the cDNA for human sarcosine dehydrogenase, a flavoenzyme defective in patients with sarcosinemia. Genomics 59 (1999) 300-308
11. Eulenburg V., Armsen W., Betz H., and Gomeza J. Glycine transporters: essential regulators of neurotransmission. Trends Biochem Sci 30 (2005) 325-333
12. Fairbanks C.A. Spinal delivery of analgesics in experimental models of pain and analgesia. Adv Drug Deliv Rev 55 (2003) 1007-1041
13. Furukawa H., and Gouaux E. Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. EMBO J 22 (2003) 2873-2885
14. Geha P.Y., Baliki M.N., Chialvo D.R., Harden R.N., Paice J.A., and Apkarian A.V. Brain activity for spontaneous pain of postherpetic neuralgia and its modulation by lidocaine patch therapy. Pain 128 (2007) 88-100
15. Gomeza J., Armsen W., Betz H., and Eulenburg V. Lessons from the knocked-out glycine transporters. Handb Exp Pharmacol (2006) 457-483
16. Hashimoto K., Fujita Y., Ishima T., Chaki S., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and d-serine. Eur Neuropsychopharmacol 18 (2008) 414-421
17. Hermanns H., Muth-Selbach U., Williams R., Krug S., Lipfert P., Werdehausen R., Braun S., and Bauer I. Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain. Neurosci Lett (2008)
18. Ishikawa A., Ambroggi F., Nicola S.M., and Fields H.L. Dorsomedial prefrontal cortex contribution to behavioral and nucleus accumbens neuronal responses to incentive cues. J Neurosci 28 (2008) 5088-5098
19. Kuchinad A., Schweinhardt P., Seminowicz D.A., Wood P.B., Chizh B.A., and Bushnell M.C. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain?. J Neurosci 27 (2007) 4004-4007
20. Lane H.Y., Liu Y.C., Huang C.L., Chang Y.C., Liau C.H., Perng C.H., and Tsai G.E. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 63 (2008) 9-12
21. Levy H.L., Coulombe J.T., and Benjamin R. Massachusetts metabolic disorders screening program: III. Sarcosinemia. Pediatrics 74 (1984) 509-513
22. Lopez-Corcuera B., Martinez-Maza R., Nunez E., Roux M., Supplisson S., and Aragon C. Differential properties of two stably expressed brain-specific glycine transporters. J Neurochem 71 (1998) 2211-2219
23. Manahan-Vaughan D., Wildforster V., and Thomsen C. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1). Eur J Neurosci 28 (2008) 1342-1350
24. Mestre C., Pelissier T., Fialip J., Wilcox G., and Eschalier A. A method to perform direct transcutaneous intrathecal injection in rats. J Pharmacol Toxicol Methods 32 (1994) 197-200
25. Metz A.E., Yau H.J., Centeno M.V., Apkarian A.V., and Martina M. Morphological and functional reorganization of rat medial prefrontal cortex in neuropathic pain. Proc Natl Acad Sci USA 106 (2009) 2423-2428
26. Millecamps M., Centeno M.V., Berra H.H., Rudick C.N., Lavarello S., Tkatch T., and Apkarian A.V. d-cycloserine reduces neuropathic pain behavior through limbic NMDA-mediated circuitry. Pain 132 (2007) 108-123
27. Morita K., Motoyama N., Kitayama T., Morioka N., Kifune K., and Dohi T. Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice. J Pharmacol Exp Ther 326 (2008) 633-645
28. Palacin M., Estevez R., Bertran J., and Zorzano A. Molecular biology of mammalian plasma membrane amino acid transporters. Physiol Rev 78 (1998) 969-1054
29. Schmidt-Wilcke T., Leinisch E., Straube A., Kampfe N., Draganski B., Diener H.C., Bogdahn U., and May A. Gray matter decrease in patients with chronic tension type headache. Neurology 65 (2005) 1483-1486
30. Scholz J., and Woolf C.J. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 10 (2007) 1361-1368
31. Tanabe M., Takasu K., Yamaguchi S., Kodama D., and Ono H. Glycine transporter inhibitors as a potential therapeutic strategy for chronic pain with memory impairment. Anesthesiology 108 (2008) 929-937
32. Tracey I., and Mantyh P.W. The cerebral signature for pain perception and its modulation. Neuron 55 (2007) 377-391
33. Tsai G., Lane H.Y., Yang P., Chong M.Y., and Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55 (2004) 452-456
34. Woolf C.J., and Salter M.W. Neuronal plasticity: increasing the gain in pain. Science 288 (2000) 1765-1769
35. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals 43. Pain 16 (1983) 109-110